Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
ITC bulking up with products rich in protein and fibre: Sanjiv Puri“India is also a protein-deficient market. We already have offerings such as high-protein atta, soya chunks and protein shakes, and we will...
Stress, poor sleep and processed food are driving heart attacks in young Indians: Ramakanta PandaYoung Indian professionals, particularly in IT and finance, are facing a heart disease crisis due to unhealthy lifestyles. Leading cardiac ...
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
Pizza Hut: From $600 loan to 20,000 stores and the new $2.7 billion twist for the global empirePizza Hut, a nearly 70-year-old American icon, has been split in a $2.7 billion deal. Yum Brands is selling its international business outs...
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
Weight-loss drugs trim UK food bills by $1 billionHouseholds with at least one user of GLP-1 weight-loss drugs bought 299 million fewer food items in the year after adoption of the medicati...
India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...